Cell markers in the recognition of acute myeloblastic leukaemia subtypes.
The diagnosis of acute myeloblastic leukaemia (AML) is based on cell morphology, cytogenetic and molecular changes, cell markers and clinical data. Our aim was to establish whether morphology and cell markers are comparable in the evaluation of AML. Bone marrow smears were analysed, and flow cytometry and monoclonal antibodies were used to determine cell type and maturity. Morphology and cell markers correlated differently in different AML subtypes.
Andoljsek
Dusan
D
University Medical Centre Ljubljana, Dept. of Haematology, Ljubljana, Slovenia.
Preloznik Zupan
Irena
I
Zontar
Darja
D
Cernelc
Peter
P
Mlakar
Uros
U
Modic
Mojca
M
Pretnar
Joze
J
Zver
Samo
S
D015415:Biomarkers / Q000032:analysis; D001854:Bone Marrow Cells / Q000737:chemistry / Q000166:cytology; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000145:classification / Q000175:diagnosis; D007947:Leukemia, Megakaryoblastic, Acute / Q000145:classification / Q000175:diagnosis; D007948:Leukemia, Monocytic, Acute / Q000145:classification / Q000175:diagnosis; D015470:Leukemia, Myeloid, Acute / Q000145:classification* / Q000175:diagnosis; D015479:Leukemia, Myelomonocytic, Acute / Q000145:classification / Q000175:diagnosis; D015473:Leukemia, Promyelocytic, Acute / Q000145:classification / Q000175:diagnosis
D015415:Biomarkers